Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2013

Open Access 01-12-2013 | Research article

Disparities in bone density measurement history and osteoporosis medication utilisation in Swiss women: results from the Swiss Health Survey 2007

Authors: Rita Born, Marcel Zwahlen

Published in: BMC Musculoskeletal Disorders | Issue 1/2013

Login to get access

Abstract

Background

Although factors associated with the utilisation of bone density measurement (BDM) and osteoporosis treatment have been regularly assessed in the US and Canada, they have not been effectively analysed in European countries. This study assessed factors associated with the utilisation of BDM and osteoporosis medication (OM) in Switzerland.

Methods

The Swiss Health Survey 2007 data included self-reported information on BDM and OM for women aged 40 years and older who were living in private households. Multivariable logistic regression analysis was used to identify sociodemographic, socioeconomic, healthcare-related and osteoporosis risk factors associated with BDM and OM utilisation.

Results

The lifetime prevalence of BDM was 25.6% (95% CI: 24.3-26.9%) for women aged 40 years and older. BDM utilisation was associated with most sociodemographic factors, all the socioeconomic and healthcare-related factors, and with major osteoporosis risk factors analysed. The prevalence of current OM was 7.8% (95% CI: 7.0-8.6%) and it was associated with some sociodemographic and most healthcare-related factors but only with one socioeconomic factor.

Conclusions

In Swiss women, ever having had a BDM and current OM were low and utilisation disparities exist according to sociodemographic, socioeconomic and healthcare-related factors. This might foster further health inequalities. The reasons for these findings should be addressed in further studies of the elderly women, including those living in institutions.
Literature
1.
Lippuner K, Johansson H, Kanis JA, Rizzoli R: Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int. 2009, 20 (7): 1131-1140. 10.1007/s00198-008-0779-8.CrossRefPubMed
2.
Federal Office of Public Health: Osteoporose und Stürze im Alter. 2004, 1-84.
3.
Schwenkglenks M, Lippuner K, Häuselmann HJ, Szucs TD: A model of osteoporosis impact in Switzerland 2000–2020. Osteoporos Int. 2005, 16 (6): 659-671. 10.1007/s00198-004-1743-x.CrossRefPubMed
4.
Kanis JA, Burlet N, Cooper C, Delmas P: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008, 19 (4): 399-428. 10.1007/s00198-008-0560-z.CrossRefPubMedPubMedCentral
5.
Siris ES, Baim S, Nattiv A: Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men. Postgrad Med. 2010, 122 (1): 82-90. 10.3810/pgm.2010.01.2102.CrossRefPubMed
6.
7.
Schwenkglenks M, Lippuner K: Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporos Int. 2007, 18 (11): 1481-1491. 10.1007/s00198-007-0390-4.CrossRefPubMed
8.
Lippuner K, Popp A, Szucs T, Schwenkglenks M: Kosteneffektivität einer Osteoporose- Behandlung nach systematischem Bevölkerungsscreening in der Schweiz: Auswirkungen der Preisreduktion des Alendronat-Originalpräparates. Pharmaco Economics. 2008, 6 (1): 19-28.
9.
Swiss Union Against Osteoporosis: Empfehlung zur Osteoporose Diagnostik, Prävention, Behandlung. 2003, 1-23.
10.
Federal Department of Home Affairs: SR 832.112.31 Krankenpflege- Leistungsverordnung KLV Art.1: Pflichtleistungen der Krankenkassen, Anhang 1. 2001
11.
Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Canada: 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J. 2002, 167 (10 Suppl): S1-S34.
12.
U. S. Preventive Services Task Force: Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002, 137 (6): 526-528.CrossRef
13.
U. S. Preventive Services Task Force: Screening for osteoporosis: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2011, 154 (5): 356-364.CrossRef
14.
Demeter S, Leslie WD, Lix L, MacWilliam L, Finlayson GS, Reed M: The effect of socioeconomic status on bone density testing in a public health-care system. Osteoporos Int. 2007, 18 (2): 153-158. 10.1007/s00198-006-0212-0.CrossRefPubMed
15.
Neuner JM, Zhang X, Sparapani R, Laud PW, Nattinger AB: Racial and socioeconomic disparities in bone density testing before and after hip fracture. J Gen Intern Med. 2007, 22 (9): 1239-1245. 10.1007/s11606-007-0217-1.CrossRefPubMedPubMedCentral
16.
Nayak S, Roberts MS, Greenspan SL: Factors associated with diagnosis and treatment of osteoporosis in older adults. Osteoporos Int. 2009, 20 (11): 1963-1967. 10.1007/s00198-008-0831-8.CrossRefPubMedPubMedCentral
17.
Vanasse A, Dagenais P, Niyonsenga T, Grégoire JP, Courteau J, Hemiari A: Bone mineral density measurement and osteoporosis treatment after a fragility fracture in older adults: regional variation and determinants of use in Quebec. BMC Musculoskelet Disord. 2005, 6: 33-10.1186/1471-2474-6-33.CrossRefPubMedPubMedCentral
18.
Brennan RM, Wactawski-Wende J, Crespo CJ, Dmochowski J: Factors associated with treatment initiation after osteoporosis screening. Am J Epidemiol. 2004, 160 (5): 475-483. 10.1093/aje/kwh245.CrossRefPubMed
19.
Federal Office of Public Health: List of pharmaceutical specialities LS. 2011
20.
Bisig B, Gutzwiller F: Gesundheitswesen Schweiz: gibt es Unter- oder Überversorgung? Die Bedeutung von Sozialschicht, Wohnregion, Nationalität, Geschlecht und Versicherungstatus. NFP45 Rüegger Verlag. 2004, 1: 1-247.
21.
Swiss Federal Statistical Office: Rapport de méthodes - Enquête suisse sur la santé 2007. 2010, 1-68.
22.
Swiss Federal Statistical Office: Schweizerische Gesundheitsbefragung 2007 in Kürze: Konzept, Methode, Durchführung. 2008, 1-9.
23.
Swiss Federal Statistical Office: Schweizerische Gesundheitsbefragung 2007: Telefonischer und schriftlicher Fragebogen. 2010, 1-126.
24.
Swiss Federal Statistical Office: Schweizerische Gesundheitsbefragung 2007: Die Indizes. 2010, 1-89.
25.
Federal Council: SR 431.012.1 Verordnung vom 30. Juni 1993 über die Durchführung von statistischen Erhebungen des Bundes (Statistikerhebungsverordnung). 1993
26.
Johnell O, Kanis JA: An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006, 17 (12): 1726-1733. 10.1007/s00198-006-0172-4.CrossRefPubMed
27.
Schmidlin K: Wie häufig und wie unterschiedlich werden Krebsvorsorgeuntersuchungen von der Schweizerischen Bevölkerung verwendet: Eine Auswertung der Schweizerischen Gesundheitsbefragung. CDSP Saphir. 2002, 2006: 1-57.
28.
Fontana M, Bischoff A: Uptake of breast cancer screening measures among immigrant and Swiss women in Switzerland. Swiss Med Wkly. 2008, 138 (49–50): 752-758.PubMed
29.
Wanner P, Raymond L, Bouchardy C: Geographical disparities in self-reported use of mammography and breast self-examination according to the Swiss health survey. Ann Oncol. 2001, 12 (4): 573-574. 10.1023/A:1011147027410.CrossRefPubMed
30.
Keller B, Stutz EZ, Tibblin M, Ackermann-Liebrich U, Faisst K, Probst-Hensch N: Screening mammographies in Switzerland: what makes female and male physicians prescribe them?. Swiss Med Wkly. 2001, 131 (21–2): 311-319.PubMed
31.
32.
Wang MC, Dixon LB: Socioeconomic influences on bone health in postmenopausal women: findings from NHANES III, 1988–1994. Osteoporos Int. 2006, 17 (1): 91-98. 10.1007/s00198-005-1917-1.CrossRefPubMed
33.
Mulherin DM, Smith JA, Price T: Is patient anxiety about osteoporosis sufficient indication for measuring bone mineral density?. Clin Exp Rheumatol. 2000, 18 (6): 789-PubMed
34.
Swiss Union Against Osteoporosis: Empfehlung zur Osteoporose Prävention Diagnostik Behandlung. 2010, 1-16.
35.
Allemann S, Saner C, Zwahlen M, Christ ER, Diem P, Stettler C: Long-term cardiovascular and non-cardiovascular mortality in women and men with type 1 and type 2 diabetes mellitus: a 30-year follow-up in Switzerland. Swiss Med Wkly. 2009, 139 (39–40): 576-583.PubMed
36.
Nayak S, Roberts MS, Greenspan SL: Factors associated with osteoporosis screening and recommendations for osteoporosis screening in older adults. J Gen Intern Med. 2009, 24 (5): 585-591. 10.1007/s11606-009-0936-6.CrossRefPubMedPubMedCentral
37.
Holroyd C, Cooper C, Dennison E: Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2008, 22 (5): 671-685. 10.1016/j.beem.2008.06.001.CrossRefPubMed
38.
Suhm N, Lamy O, Lippuner K, OsteoCare study group: Management of fragility fractures in Switzerland: results of a nationwide survey. Swiss Med Wkly. 2008, 138 (45–6): 674-683.PubMed
39.
Schürch MA, Rizzoli R, Mermillod B, Vasey H, Michel JP, Bonjour JP: A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res. 1996, 11 (12): 1935-1942.CrossRefPubMed
Metadata
Title
Disparities in bone density measurement history and osteoporosis medication utilisation in Swiss women: results from the Swiss Health Survey 2007
Authors
Rita Born
Marcel Zwahlen
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2013
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/1471-2474-14-10

Other articles of this Issue 1/2013

BMC Musculoskeletal Disorders 1/2013 Go to the issue

Research article

What do we tell patients about elective total hip replacement in the UK? An analysis of patient literature

Research article

Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry

Research article

Does medial support decrease major complications of unstable proximal humerus fractures treated with locking plate?

Research article

Differences between patients with chronic widespread pain and local chronic low back pain in primary care - a comparative cross-sectional analysis

Erratum

Erratum to: Amsterdam wrist rules: a clinical decision aid

Research article

Hand function in children with radial longitudinal deficiency